Product Detail
6-Desacetyl-6-ethoxyvinyl-N-Boc Palbociclib-d4
Palbociclib Stable Isotopes
Stock Status: Enquire
Live
For Research & Analytical Purposes. Not for Personal use.
Category
Stable Isotopes
API Family
Palbociclib
Storage
Refer MSDS for complete information.
Hazard Information
Refer MSDS for complete information.
6-Desacetyl-6-ethoxyvinyl-N-Boc Palbociclib-d4 Product Information
6-Desacetyl-6-ethoxyvinyl-N-Boc Palbociclib-d4 is listed under Stable Isotopes. It is associated with Palbociclib and is intended for analytical research, quality control and pharmaceutical reference standard applications. The product is supplied by Clearsynth under CAT No. CS-T-100574.
Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight, stock enquiry details and supporting documentation.
Technical Data
Product Name
6-Desacetyl-6-ethoxyvinyl-N-Boc Palbociclib-d4
CAS No.
-
CAT No.
CS-T-100574
Molecular Formula
C31H37D4N7O4
Molecular Weight
579.73
Category
API Family
Storage Condition
Refer MSDS for complete information.
SMILES
[2H]C1([2H])CN(C2=CC=C(NC3=NC=C(C(C)=C(C(OCC)=C)C(N4C5CCCC5)=O)C4=N3)N=C2)CC([2H])([2H])N1C(OC(C)(C)C)=O
IUPAC Name
tert-butyl 4-(6-((8-cyclopentyl-6-(1-ethoxyvinyl)-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-2,2,6,6-d4-carboxylate
Hazard Compound
Refer MSDS for complete information.
Description
Overview
"6-Desacetyl-6-ethoxyvinyl-N-Boc Palbociclib-d4 is an intermediate in synthesizing Palbociclib-d4 (P139901), an isotope labelled compound of Palbociclib (P139900). Palbociclib (P139900) is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6."
Synonyms
6-Desacetyl-6-ethoxyvinyl-N-Boc Palbociclib-d4
Application Notes
"6-Desacetyl-6-ethoxyvinyl-N-Boc Palbociclib-d4 is an intermediate in synthesizing Palbociclib-d4 (P139901), an isotope labelled compound of Palbociclib (P139900). Palbociclib (P139900) is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6."
References
"Finn, R., et al.: Breast Cancer Res., 11, 5 (2009)"
